Abstract: AIM:To investigate the effect of rosuvastatin on coronary flow reserve(CFR) and high-sensitivity C-reactive protein(hsCRP) in patients with slow coronary flow.METHODS:A total of 48 patients with slow coronary flow but normal coronary angiography were included in this study.Patients were divided into rosuvastatin group(20 mg/day for 6 months,n=26) and control group(non-statin,n=22) and blood cholesterol and hsCRP were measured.Doppler coronary flow velocity and Doppler reserve measurement of distal left anterior descending artery were recorded at rest and adenosine infusion-induced hyperemia state.CFR was calculated by the ratio of maximal hyperemia and baseline peak diastolic coronary flow velocity(hCFV and bCFV) before and after rosuvastatin treatment.RESULTS:After treatment for 6 months,total cholesterol(TC) and low-density lipoprotein cholesterol(LDL-C) levels in rosuvastatin group were significantly lower than those in control group TC:(3.2±0.9) mmol/L vs.(5.4±1.2) mmol/L,P<0.05;LDL-C:(2.1±0.7) mmol/L vs.(3.4±0.8) mmol/L,P<0.05.hsCRP in rosuvastatin group was significantly lower than in control group (2.1±1.4) mg/L vs.(3.7±2.1) mg/L,P<0.05.Compared with those in control group and rosuvastatin group before treatment,treatment for 6 months with rosuvastatin reduced bCFV (21±6)cm/sec vs.(26±5)cm/sec and(21±6)cm/sec vs.(25±7)cm/sec,P<0.05,increased hCFV (71±9) cm/sec vs.(56±8) cm/sec and(71±9) cm/sec vs.(56±10) cm/sec,P<0.05,and increased CFR (3.2±0.6) cm/sec vs.(2.1±0.5) cm/sec and(3.2±0.6) cm/sec vs.(2.2±0.4) cm/sec,P<0.05.CONCLUSION:Rosuvastatin may effectively improve coronary flow reserve and reduce hsCRP in patients with slow coronary flow.